Aktis Oncology News, Aktis Oncology Quote, AKTS Quote

Aktis Oncology (NQ:AKTS) Delayed: 18.81 -1.73 (8.42%)

Prev. Close

$20.54

Today 6M 1Y 5Y

Open

$20.54

52 Wk High

$5.77

52 Wk Low

$1.51

Day High

$20.54

Day Low

$18.81

P/E

N/A

EPS

$0.00

Volume

217,370

Friends, Peers and Foes (?): LLY (more...)

ALERTS | RSS

Feb 24, 2026 04:05 PM Aktis Oncology to Present at Upcoming March Investor Conferences
Feb 24, 2026 08:00 AM Aktis Oncology receives FDA fast track designation for cancer drug
Feb 24, 2026 08:00 AM Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
Feb 3, 2026 06:13 AM Leerink Partners Starts Akoustis Technologies (AKTS) at Outperform
Feb 3, 2026 06:05 AM BofA Securities Starts Akoustis Technologies (AKTS) at Buy
Feb 3, 2026 05:29 AM TD Cowen Starts Akoustis Technologies (AKTS) at Buy
Feb 3, 2026 02:29 AM JPMorgan Starts Akoustis Technologies (AKTS) at Overweight
Jan 9, 2026 12:58 PM Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
Jan 5, 2026 07:50 AM Aktis Oncology seeks to raise $212 million in Nasdaq IPO
Jan 5, 2026 06:34 AM Aktis Oncology (AKTS) files for 11.775M share IPO at $16-$18/sh

Entities mentioned with AKTS

View All Entities